Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              PharmaMar

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              PharmaMar Gets Spanish Medicines Agency Authorization for APLICOV-PC Clinical Trial With Aplidin® for the Treatment of COVID-19

              Contact the Supplier

              Lead Product(s): Plitidepsin

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 28, 2020

              Details:

              The objective of the trial is to evaluate the efficacy and safety of plitidepsin in patients with COVID-19 requiring hospital admission.

              Oryzon Genomics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              ORYZON to Initiate ESCAPE, Phase II Clinical Trial to Test Efficacy of Vafidemstat in Severely Ill COVID-19 Patients

              Contact the Supplier

              Lead Product(s): Vafidemstat

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 24, 2020

              Details:

              ORYZON has received approval from the Spanish Drug Agency to conduct a Phase II clinical trial with vafidemstat in seriously ill COVID-19 patients.

              PharmaMar

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              PharmaMar has submitted a Phase II clinical trial of Aplidin for the treatment of COVID-19

              Contact the Supplier

              Lead Product(s): Plitidepsin

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 02, 2020

              Details:

              The goal of the trial is to evaluate the efficacy and safety of plitidepsin in hospitalized patients as a treatment for COVID-19 (SARS-CoV-2).

              PharmaCompass__DigitalAd